Plasma mexiletine concentrations following combined oral and intramuscular administration.
Mexiletine in doses of 50, 100 and 400 mg was administered by intramuscular injection to a healthy subject and the resulting plasma concentrations were compared with those after 100 mg given intravenously. The bioavailability of mexiletine given by this route is complete and the kinetics are linear with dose. Plasma mexiletine concentrations resulting from 200 mg given orally with either two 4-ml intramuscular injections each containing 100 mg (Mexitil--for intravenous use) or one 2-ml intramuscular injection of an experimental preparation containing 200 mg were compared in 3 and 6 normal subjects respectively. Plasma levels within the therapeutic range of 0.75-2 microgram/ml were attained at mean times of 28.7 and 42.5 min respectively. Apart from raised plasma creatine phosphokinase levels (as would be expected following an intramuscular injection) the tolerability of intramuscular mexiletine injections was satisfactory. Further studies in patients will be required to determine whether the combined oral and intramuscular administration of mexiletine is of value in acute myocardial infarction.
D000284:Administration, Oral; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D007273:Injections, Intramuscular; D007700:Kinetics; D008801:Mexiletine / Q000008:administration & dosage / Q000097:blood*; D011437:Propylamines / Q000097:blood*
D011437:Propylamines; D008801:Mexiletine; D003402:Creatine Kinase